Regeneron Jumps on ‘Ultimate Validation’ as Trump Treated
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. climbed the most in more than three months on Monday after U.S. President Donald Trump received the biotech company’s antibody cocktail to treat Covid-19.
President Trump’s treatment was the “ultimate validation” for Regeneron, according to SVB Leerink analyst Geoffrey Porges.